Selected products in development
Novartis is consistently rated as having one of the industry’s most respected development pipelines, with more than 160 projects in clinical development, as of December 31, 2020. We highlight some promising programs, including new molecules and existing treatments that are under investigation for new indications.
AVXS-201 (OAV201) is an investigational gene therapy for Rett syndrome, a rare genetic neurological disorder.
LMI070 (branaplam) is a treatment in development for Huntington’s disease, a rare, inherited neurodegenerative disease that leads to progressive disability and death. It is also in development for spinal muscular atrophy, a genetic neuromuscular disease.
MBG453 (sabatolimab) is an investigational treatment for myelodysplastic syndrome and acute myeloid leukemia, forms of blood cancer.
KAF156 (ganaplacide) is a treatment in development for malaria. This new class of molecules has the potential to clear infections and block parasite transmission.
Cosentyx (secukinumab) is a treatment in development for various inflammatory conditions. It is approved for other inflammatory conditions such as moderate-to-severe plaque psoriasis.
LOU064 (remibrutinib) is a treatment in development for chronic spontaneous urticaria/chronic idiopathic urticaria, a skin condition. It is also in development for an autoimmune disease called Sjögren’s syndrome.
QGE031 (ligelizumab) is an investigational treatment for chronic spontaneous urticaria/chronic idiopathic urticaria, a skin condition.
177Lu-PSMA-617 is a radioligand therapy in development for metastatic castration-resistant prostate cancer as well as earlier forms of the disease.
LNA043 is a treatment in development for osteoarthritis.
UNR844 is an investigational treatment for presbyopia, the age-related loss of near-distance vision.
Beovu (brolucizumab) is a treatment in development for various eye diseases. It is approved to treat neovascular (wet) age-related macular degeneration.
ACZ885 (canakinumab) is an antibody treatment in development for non-small cell lung cancer. ACZ885 is approved as Ilaris for various inflammatory conditions, including cryopyrin-associated periodic syndrome and some forms of arthritis.
Kisqali (ribociclib) is in development to treat hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer as an adjuvant therapy. It is approved for patients with more advanced stages of this cancer.
KJX839 (inclisiran, approved in the EU as Leqvio) is a treatment that reduces LDL cholesterol in patients with atherosclerotic cardiovascular disease. Novartis continues to study KJX839 to treat high cholesterol.
Entresto (sacubitril/valsartan) is a treatment in development for several cardiovascular conditions. It is approved for heart failure with reduced ejection fraction.
TQJ230 is an investigational treatment for the secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a).
LNP023 (iptacopan) is a treatment in development for a kidney disease called IgA nephropathy (IgAN). It is also in development to treat other rare kidney and blood diseases.
CFZ533 (iscalimab) is an investigational treatment for several autoimmune diseases. It is also in development to prevent graft rejection in transplant patients.
R&D SPENDING
9.0 bn
Our investment in research and development in 2020, amounting to 18.5% of net sales (USD)
Pipeline Projects in clinical Development
160+
Projects with ongoing clinical trials in Phases I to III
Potential blockbusters
25+
The number of our assets in development with the potential to be blockbuster medicines
For more information about the Novartis pipeline and progress on individual development programs: